As of Feb 16
| +1.14 / +0.94%|
The 18 analysts offering 12-month price forecasts for Alnylam Pharmaceuticals Inc have a median target of 157.50, with a high estimate of 205.00 and a low estimate of 56.00. The median estimate represents a +28.17% increase from the last price of 122.88.
The current consensus among 19 polled investment analysts is to Buy stock in Alnylam Pharmaceuticals Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.